Reduced free IGF-I and increased IGFBP-3 proteolysis in turner syndrome: Modulation by female sex steroids

American Journal of Physiology - Endocrinology and Metabolism

Volumn 280, Issue 2 43-2, 2001, Pages

  Gravholt, Claus Højbjerg ^a   Frystyk, Jan ^a   Flyvbjerg, Allan ^a   Ørskov, Hans ^a   Christiansen, Jens Sandahl ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

17 estradiol; Final height; Free unsulin like growth factor I; Proteolysis; Total insulin like growth factor I; Turner syndrome; Unsulin like growth factor binding protein 3

Indexed keywords

ESTRADIOL; NORETHISTERONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TRISEQUENS;

ADULT; ARTICLE; BODY HEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; STEROID THERAPY; TURNER SYNDROME;

EID: 0035017119     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.2001.280.2.e308     Document Type: Article

References (51)

1. Apter D, Lenko HL, Perheentupa J, Soderholm A, and Vihko R. Subnormal pubertal increases of serum androgens in Turner's syndrome. Horm Res 16: 164-173, 1982.
2. Bang P, Brismar K, and Rosenfeld RG. Increased proteolysis of insulin-like growth factor-binding protein-3 (IGFBP-3) in noninsulin-dependent diabetes mellitus serum, with elevation of a 29-kilodalton (kDa) glycosylated IGFBP-3 fragment contained in the approximately 130-to 150-kDa ternary complex. J Clin Endocrinol Metab 78: 1119-1127, 1994.
3. Bang P and Fielder PJ. Human pregnancy serum contains at least two distinct proteolytic activities with the ability to degrade insulin-like growth factor binding protein-3. Endocrinology 138: 3912-3917, 1997.
4. Bang P, Nygren J, Carlsson-Skwirut C, Thorell A, and Ljungqvist O. Postoperative induction of insulin-like growth factor binding protein-3 proteolytic activity: relation to insulin and insulin sensitivity. J Clin Endocrinol Metab 83: 2509-2515, 1998.
5. Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab 278: E967-E976, 2000.
6. Bellantoni MF, Vittone J, Campfield AT, Bass KM, Harman SM, and Blackman MR. Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center study. J Clin Endocrinol Metab 81: 2848-2853 1996.
7. Blethen SL, Albertsson Wikland K, Faklis EJ, and Chasalow FI. Circulating growth hormone isoforms in girls with Turner's syndrome. J Clin Endocrinol Metab 78: 1439-1443, 1994.
8. Cox GN, McDermott MJ, Merkel E, Stroh CA, Ko SC, Squires CH, Gleason TM, and Russell D. Recombinant human insulin-like growth factor (IGF)-binding protein-1 inhibits somatic growth stimulated by IGF-I and growth hormone in hypophysectomized rats. Endocrinology 135: 1913-1920, 1994.
9. Cuttler L, Van Vliet G, Conte FA, Kaplan SL, and Grumbach MM. Somatomedin-C levels in children and adolescents with gonadal dysgenesis: differences from age-matched normal females and effect of chronic estrogen replacement therapy. J Clin Endocrinol Metab 60: 1087-1092, 1985.
10. Cwyfan HS, Cotterill AM, Molloy AR, Cassell TB, Braude N, Hinds CJ, Wass JA, and Holly JM. The induction of specific proteases for insulin-like growth factor-binding proteins following major heart surgery. J Endocrinol 135: 135-145, 1992.
11. Daughaday WH and Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 10: 68-91, 1989.
12. Davenport ML, Isley WL, Pucilowska JB, Pemberton LB, Lyman B, Underwood LE, and Clemmons DR. Insulin-like growth factor-binding protein-3 proteolysis is induced after elective surgery. J Clin Endocrinol Metab 75: 590-595, 1992.
13. Davies SC, Wass JA, Ross RJ, Cotterill AM, Buchanan CR, Coulson VJ, and Holly JM. The induction of a specific protease for insulin-like growth factor binding protein-3 in the circulation during severe illness. J Endocrinol 130: 469-473, 1991.
14. Flyvbjerg A, Kessler U, Dorka B, Funk B, Ørskov H, and Kiess W. Transient increase in renal insulin-like growth factor binding proteins during initial kidney hypertrophy in experimental diabetes in rats. Diabetologia 35: 589-593, 1992.
15. Flyvbjerg A, Mogensen O, Mogensen B, and Nielsen OS. Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. J Clin Endocrinol Metab 82: 2308-2313, 1997.
16. Foster CM, Borondy M, Markovs ME, Hopwood NJ, Kletter GB, and Beitins IZ. Growth hormone bioactivity in girls with Turner's syndrome: correlation with insulin-like growth factor I. Pediatr Res 35: 218-222, 1994.
17. Friend KE, Hartman ML, Pezzoli SS, Clasey JL, and Thorner MO. Both oral and transdermal estrogen increase growth hormone release in postmenopausal women: a clinical research center study. J Clin Endocrinol Metab 81: 2250-2256, 1996.
18. Frystyk J, Dinesen B, and Ørskov H. Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth Regul 5: 169-176, 1995.
19. Frystyk J, Hussain M, Skjaerbaek C, Pørksen N, Froesch ER, and Ørskov H. The pharmacokinetics of free insulin-like growth factor-I in healthy subjects. Growth 9: 150-156, 1999.
20. Frystyk J, Skjaerbaek C, Dinesen B, and Ørskov H. Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEBS Lett 348: 185-191, 1994.
21. Frystyk J, Vestbo E, Skjaerbaek C, Mogensen CE, and Ørskov H. Free insulin-like growth factors in human obesity. Metabolism 44: 37-44, 1995.
22. Gravholt CH and Naeraa RW. Reference values for body proportions and body composition in adult women with Turner's syndrome. Am J Med Genet 72: 403-408, 1997.
23. Gravholt CH, Naeraa RW, Fisker S, and Christiansen JS. Body composition and physical fitness are major determinants of the growth hormone-IGF axis aberrations in adult Turner syndrome, with important modulations by treatment with 17-beta-estradiol. J Clin Endocrinol Metab 82: 2570-2577, 1997.
24. Gravholt CH, Naeraa RW, Nyholm B, Gerdes U, Christiansen E, Schmitz O, and Christiansen JS. Glucose metabolism, lipid metabolism, and cardiovascular risk factors in adult Turner syndrome: the impact of sex hormone replacement. Diabetes Care 21: 1062-1070, 1998.
25. Gravholt CH, Veldhuis JD, and Christiansen JS. Increased disorderliness and decreased mass and daily rate of endogenous growth hormone secretion in adult Turner syndrome: the impact of body composition, physical fitness and treatment with sex hormones. Growth 8: 289-298, 1998.
26. Heitmann BL. Prediction of body water and fat in adult Danes from measurement of electrical impedance: a validation study. Int J Obes 14: 789-802, 1990.
27. Helle SI, Omsjo IH, Hughes SCC, Botta L, Huls G, Holly JM, and Lonning PE. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study. Clin Endocrinol (Oxf) 45: 727-732, 1996.
28. Hossenlopp P, Segovia B, Lassarre C, Roghani M, Bredon M, and Binoux M. Evidence of enzymatic degradation of insulin-like growth factor-binding proteins in the 150K complex during pregnancy. J Clin Endocrinol Metab 71: 797-805, 1990.
29. Hossenlopp P, Seurin D, Segovia-Quinson B, Hardouin S, and Binoux M. Analysis of serum insulin-like growth factor binding proteins using western blotting: use of the method for titration of the binding proteins and competitive binding studies. Anal Biochem 154: 138-143, 1986.
30. Ishikawa M, Yokoya S, Tachibana K, Hasegawa Y, Yasuda T, Tokuhiro E, Hashimoto Y, and Tanaka T. Serum levels of 20-kilodalton human growth hormone (GH) are parallel those of 22-kilodalton human GH in normal and short children. J Clin Endocrinol Metab 84: 98-104, 1999.
31. Jensen J, Christiansen C, and Rodbro P. Oestrogen-progestogen replacement therapy changes body composition in early post-menopausal women. Maturitas 8: 209-216, 1986.
32. Lassarre C and Binoux M. Insulin-like growth factor binding protein-3 is functionally altered in pregnancy plasma. Endocrinology 134: 1254-1262, 1994.
33. Lawrence JB, Oxvig C, Overgaard MT, Sottrup-Jensen L, Gleich GJ, Hays LG, Yates JR, and Conover CA. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci USA 96: 3149-3153, 1999.
34. Maor G, Segev Y, and Phillip M. Testosterone stimulates insulin-like growth factor-I and insulin-like growth factor-I-receptor gene expression in the mandibular condyle - a model of endochondral ossification. Endocrinology 140: 1901-1910, 1999.
35. Massarano AA, Brook CG, Hindmarsh PC, Pringle PJ, Teale JD, Stanhope R, and Preece MA. Growth hormone secretion in Turner's syndrome and influence of oxandrolone and ethinyl oestradiol. Arch Dis Child 64: 587-592, 1989.
36. Phillips SK, Rook KM, Siddle NC, Bruce SA, and Woledge RC. Muscle weakness in women occurs at an earlier age than in men, but strength is preserved by hormone replacement therapy. Clin Sci (Colch) 84: 95-98, 1993.
37. Preece MA, Taylor AM, Holder AT, and Daggett P. The clinical application of somatomedin bioassays. In: Proceedings of the Serono Symposia, edited by Giordano G, van Wyk JJ, and Minuto F. New York: Academic, 1979, p. 263-270.
38. Ranke MB, Blum WF, Haug F, Rosendahl W, Attanasio A, Enders H, Gupta D, and Bierich JR. Growth hormone, somatomedin levels and growth regulation in Turner's syndrome. Acta Endocrinol 116: 305-313, 1987.
39. Reiter JC, Craen M, and Van Vliet G. Decreased growth hormone response to growth hormone-releasing hormone in Turner's syndrome: relation to body weight and adiposity. Acta Endocrinol 125: 38-42, 1991.
40. Ross JL, Cassorla FG, Skerda MC, Valk IM, Loriaux DL, and Cutler GBJ. A preliminary study of the effect of estrogen dose on growth in Turner's syndrome. N Engl J Med 309: 1104-1106, 1983.
41. Ross JL, Long LM, Loriaux DL, and Cutler GBJ. Growth hormone secretory dynamics in Turner syndrome. J Pediatr 106: 202-206, 1985.
42. Saenger P, Schwartz E, Wiedemann E, Levine LS, Tsai M, and New MI. The interaction of growth hormone, somatomedin and oestrogen in patients with Turner's syndrome. Acta Endocrinol 81: 9-18, 1976.
43. Sas TC, Muinck Keizer-Schrama SM, Stijnen T, Jansen M, Otten BJ, Hoorweg-Nijman JJ, Vulsma T, Massa GG, Rouwe CW, Reeser HM, Gerver WJ, Gosen JJ, Rongen-Westerlaken C, and Drop SL. Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. J Clin Endocrinol Metab 84: 4607-4612, 1999.
44. Skjaerbaek C, Vahl N, Frystyk J, Hansen TB, Jorgensen JO, Hagen C, Christiansen JS, and Ørskov H. Serum free insulin-like growth factor-I in growth hormone-deficient adults before and after growth hormone replacement. Eur J Endocrinol 137: 132-137, 1997.
45. Sylven L, Hagenfeldt K, Brondum NK, and von Schoultz B. Middle-aged women with Turner's syndrome. Medical status, hormonal treatment and social life. Acta Endocrinol 125: 359-365, 1991.
46. Weissberger AJ, Ho KK, and Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab 72: 374-381, 1991.
47. Westwood M, Gibson JM, Pennells LA, and White A. Modification of plasma insulin-like growth factors and binding proteins during oral contraceptive use and the normal menstrual cycle. Am J Obstet Gynecol 180: 530-536, 1999.
48. Westwood M, Gibson JM, Williams AC, Clayton PE, Hamberg O, Flyvbjerg A, and White A. Hormonal regulation of circulating insulin-like growth factor-binding protein-1 phosphorylation status. J Clin Endocrinol Metab 80: 3520-3527, 1995.
49. Wiedemann E, Schwartz E, and Frantz AG. Acute and chronic estrogen effects upon serum somatomedin activity, growth hormone, and prolactin in man. J Clin Endocrinol Metab 42: 942-952, 1976.
50. Wit JM, Massarano AA, Kamp GA, Hindmarsh PC, van Es A, Brook CG, Preece MA, and Matthews DR. Growth hormone secretion in patients with Turner's syndrome as determined by time series analysis. Acta Endocrinol 127: 7-12, 1992.
51. Zadik Z, Landau H, Chen M, Altman Y, and Lieberman E. Assessment of growth hormone (GH) axis in Turner's syndrome using 24-hour integrated concentrations of GH, insulin-like growth factor-I, plasma GH-binding activity, GH binding to IM9 cells, and GH response to pharmacological stimulation. J Clin Endocrinol Metab 75: 412-416, 1992.